Stock listing
BX Swiss:NUVL Nuvalent, Inc. Aktie
Swiss listing (BX Swiss) of Nuvalent, Inc. · home listing NASDAQ:NUVL
Follow Nuvalent, Inc. into a list and get an email when it puts out news.

- Ticker
- BX Swiss:NUVL
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- BX Swiss
- Currency
- CHF
What changed lately
Latest news release · Jun 10, 2026
Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK
Latest news
Nuvalent, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 114 in all · newest Jun 10, 2026 · oldest 2021
Where Nuvalent, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:NUVL · Home listing | NASDAQ | United States | USD |
| BX Swiss:NUVL · This page | BX Swiss | Switzerland | CHF |
| BOATS:NUVL | BOATS | United States | USD |
Valuation
Statements: 4 quarters to Mar 31, 2026
- Enterprise value
- No market cap
- P/E
- No market cap
- EV/sales
- No market cap
- EV/EBITDA
- No market cap
- Price/book
- No market cap
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- Under 6 months of closes
Forecasts
8 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 124.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -5.50 · 10 analysts
- Revenue, year to Dec 2026
- 10.74M · 10 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Constantin Fest | Investor Relations |
| Georg Pirmin Meyer | Chief International Officer |
Board
| Director | Role |
|---|---|
| Christy Oliger | Director |
| Grant Bogle | Director |
| Ron Squarer | Director |
Events
| Quarter | Results |
|---|---|
| Q1 2026 | May 7, 2026 · Before open |
| Q4 2025 | Feb 26, 2026 |
| Q3 2025 | Oct 30, 2025 · Before open |
| Q2 2025 | Aug 7, 2025 · Before open |
| Q1 2025 | May 8, 2025 |
| Q4 2024 | Feb 27, 2025 · Before open |
| Q3 2024 | Nov 12, 2024 · Before open |
| Q2 2024 | Aug 8, 2024 · Before open |
| Q1 2024 | May 9, 2024 · Before open |
| Q4 2023 | Feb 27, 2024 · Before open |
All 20 quarters
| Quarter | Results |
|---|---|
| Q3 2023 | Nov 14, 2023 · Before open |
| Q2 2023 | Aug 10, 2023 · Before open |
| Q1 2023 | May 11, 2023 · Before open |
| Q4 2022 | Mar 16, 2023 · Before open |
| Q3 2022 | Nov 10, 2022 · Before open |
| Q2 2022 | Aug 10, 2022 · Before open |
| Q1 2022 | May 12, 2022 · Before open |
| Q4 2021 | Mar 29, 2022 · Before open |
| Q3 2021 | Nov 10, 2021 · Before open |
| Q2 2021 | Sep 8, 2021 · Before open |
Financings
| Raise | Date |
|---|---|
| Public offering of shares of Class A common stock Closed: US$500M raised · US$101 a share · J.P. Morgan +3 Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), TD Cowen (co-lead), Cantor (co-lead) | Nov 24, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 307.0M | 217.8M | 113.2M | 63.7M | 35.6M | 15.4M | 9.75M |
| Selling, general and administrative | 107.3M | 62.6M | 36.2M | 22.4M | 10.3M | 1.50M | 612.0K |
| Operating income | -414.3M | -280.4M | -149.5M | -86.1M | -45.8M | -16.9M | -10.4M |
| Depreciation and amortization | 414.3M | 280.4M | 23.3M | 373.0K | 215.0K | 2.35M | 1.45M |
| EBITDA | 0 | 0 | -126.2M | -85.7M | -45.6M | -14.6M | -8.91M |
| Interest expense | 38.3M | 23.3M | 4.25M | 521.0K | 0 | 0 | |
| Income before tax | -424.8M | -260.0M | -126.2M | -81.9M | -46.3M | -14.6M | -11.8M |
| Income tax | 585.0K | 764.0K | -167.9K | -8.51M | 521.0K | -2.35M | 1.45M |
| Net income | -425.4M | -260.8M | -126.2M | -73.3M | -46.3M | -14.6M | -11.8M |
| Earnings per share, basic | -5.85 | -3.93 | -2.17 | -1.48 | -2.13 | -0.64 | -0.24 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 261.7M | 145.7M | 335.4M | 241.8M | 68.5M | 10.3M | 3.02M |
| Short-term investments | 1.11B | 972.6M | 384.5M | 230.4M | 219.6M | 0 | |
| Receivables | 4.47M | 3.20M | |||||
| Current assets | 1.39B | 1.13B | 726.5M | 478.0M | 290.6M | 10.6M | 3.32M |
| Total assets | 1.41B | 1.14B | 732.4M | 482.5M | 293.8M | 10.6M | 3.32M |
| Accounts payable | 30.2M | 5.22M | 9.27M | 7.20M | 2.89M | 1.25M | 723.0K |
| Current liabilities | 91.2M | 54.0M | 31.8M | 19.5M | 8.79M | 4.38M | 4.35M |
| Long-term debt | 2.23M | 2.17M | |||||
| Total debt | 2.23M | 2.17M | |||||
| Total liabilities | 164.4M | 72.0M | 31.8M | 19.5M | 8.79M | 42.0M | 20.6M |
| Shareholders' equity | 1.25B | 1.07B | 700.6M | 463.0M | 285.0M | -31.3M | -17.3M |
| Shares outstanding | 72.7M | 66.4M | 58.2M | 49.7M | 21.8M | 22.9M | 48.3M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -275.2M | -185.1M | -99.7M | -65.0M | -40.0M | -14.9M | -9.64M |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | -275.2M | -185.1M | -99.7M | -65.0M | -40.0M | -14.9M | -9.64M |
| Cash from investing | -124.1M | -573.5M | -143.5M | -10.7M | -220.0M | -220.0M | -220.0M |
| Cash from financing | 515.3M | 568.9M | 336.8M | 248.9M | 318.2M | 22.3M | 22.3M |
| Share buybacks | 387.0K | 249.8M | 318.9M | ||||
| Change in cash | 116.1M | -189.7M | 93.6M | 173.3M | 58.2M | 7.32M | -9.64M |
Cap table
Built by 6ix from Nuvalent, Inc.’s releases · as of Nov 24, 2025
- Common shares
- 73,692,987
- Fully diluted
- 73,692,987
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 73,692,987 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 73,692,987 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| James Flynn Other companies: Lite Strategy, Inc. (Non-Executive Director · Since at least Oct 31, 2023); Larimar Therapeutics, Inc. (Director · Since at least May 28, 2020); Synlogic Inc (Director · Mar 19, 2024 – Apr 26, 2025 · Past); BiomX Inc. (Director · Mar 15, 2024 – Apr 21, 2025 · Past); RiceBran Technologies (Director · Jan 3, 2024 – Jan 3, 2024 · Past); Oruka Therapeutics, Inc. (Director · Dec 15, 2022 – Jan 30, 2024 · Past); CareMax Inc (Director · Nov 17, 2022 – Nov 17, 2023 · Past); ARS Pharmaceuticals, Inc. (Director · Nov 8, 2022 – Nov 8, 2022 · Past); Da32 Life Science Tech Acquisition Corp (Director · Jul 27, 2021 – Jul 28, 2023 · Past); Oncorus Inc (Director · Oct 1, 2020 – Feb 17, 2021 · Past); Acutus Medical Inc. (Director · Aug 5, 2020 – Jan 27, 2025 · Past); Deerfield Healthcare Technology Acquisitions Corp (Director · Jul 16, 2020 – Jul 21, 2020 · Past); Q32 Bio Inc. (Director · Mar 27, 2018 – Jun 6, 2019 · Past); AdaptHealth Corp. (Director · Feb 15, 2018 – Nov 8, 2019 · Past); Alpine Immune Sciences Inc (Director · Sep 12, 2016 – Sep 12, 2016 · Past); AveXis Inc (Director · Sep 3, 2015 – Feb 10, 2016 · Past) | Director · Since at least Jul 28, 2021 |
| Christy Oliger Other companies: Zenas BioPharma, Inc. (Director · Since at least Aug 13, 2026); Bicara Therapeutics Inc. (Director · Since at least Jul 28, 2026); LAVA Therapeutics NV (Director · Since at least Jan 1, 2025); Vera Therapeutics, Inc. (Director · Since at least Jun 7, 2024); Replimune Group, Inc. (Director · Since at least Dec 1, 2021); Karyopharm Therapeutics Inc. (Director · Since at least Aug 28, 2020); RayzeBio, Inc. (Director · Sep 14, 2023 – Feb 26, 2024 · Past); Sierra Oncology Inc (Director · Jun 2, 2021 – Jul 1, 2022 · Past); Reata Pharmaceuticals Inc (Director · Apr 15, 2021 – Sep 26, 2023 · Past) | Director · Since at least Jun 18, 2025 |
| Sapna Srivastava Other companies: Alumis Inc. (Independent Board Member · Since at least Jun 27, 2024); Aura Biosciences, Inc. (Director · Since at least Oct 28, 2021); Tourmaline Bio Inc. (Director · Since at least May 6, 2021); Innoviva, Inc. (Director · Jan 1, 2023 – Jun 17, 2024 · Past); Social Capital Suvretta Holdings Corp II (Director · Jun 29, 2021 – Jun 29, 2021 · Past); Intellia Therapeutics, Inc. (Chief Financial & Stategy Offr · May 5, 2016 – May 5, 2016 · Past); Medavail Holdings Inc (Director · Feb 8, 2013 – Jan 12, 2015 · Past) | Director · Since at least Jul 28, 2021 |
| Andrew A F Hack Other companies: Mersana Therapeutics Inc (Director · Since at least Jun 27, 2017); Atea Pharmaceuticals, Inc. (Director · Oct 29, 2020 – Nov 3, 2020 · Past); BCLS Acquisition Corp (Chief Financial Officer, Director · Oct 21, 2020 – Oct 26, 2020 · Past); Dynavax Technologies Corporation (Director · Aug 12, 2019 – Aug 8, 2023 · Past); Allena Pharmaceuticals Inc (Director · Jun 8, 2018 – Nov 17, 2020 · Past); Editas Medicine, Inc. (Chief Financial Officer · Feb 2, 2016 – Feb 4, 2019 · Past) | Director · Jul 28, 2021 – Dec 11, 2024 · Past |
| Anna Protopapas Other companies: Mersana Therapeutics Inc (Director · Since at least Jun 27, 2017); Dicerna Pharmaceuticals Inc (Director · Jan 23, 2019 – Jun 3, 2021 · Past); Bioverativ Inc (Director · Feb 28, 2017 – Mar 8, 2018 · Past); Ariad Pharmaceuticals Inc (Director · Feb 1, 2016 – Feb 16, 2017 · Past) | Director · Since at least Mar 30, 2022 |
| Ron Squarer Other companies: ADC Therapeutics SA (Director · Since at least Jan 2, 2024); Travere Therapeutics, Inc. (Director · Since at least May 14, 2021); Deciphera Pharmaceuticals LLC (Director · Jan 15, 2021 – Jun 11, 2024 · Past) | Director · Since at least Dec 10, 2025 |
| Cameron Wheeler Other companies: Oncorus Inc (Director · Oct 1, 2020 – Oct 1, 2020 · Past); Q32 Bio Inc. (Director · Mar 27, 2018 – Jun 6, 2019 · Past) | Director · Since at least Jul 28, 2021 |
| Grant Bogle Other companies: Epizyme Inc (President and CEO, Director · Sep 2, 2019 – Aug 12, 2022 · Past); Tesaro Inc (Sr. VP, Chief Commercial Ofc · Jul 13, 2015 – Jan 22, 2019 · Past) | Director · Since at least Dec 5, 2024 |
| Ron Squarer Other companies: ADC Therapeutics SA (Chairman · Since at least Jun 3, 2026); Travere Therapeutics, Inc. (Director · Since at least May 21, 2026) | Director · Since at least Dec 10, 2025 |
| Alexandra Balcom Other companies: Crescent Biopharma, Inc. (Director · Since at least Jun 13, 2025) | Chief Financial Officer · Since at least Jul 28, 2021 |
All 24 people
| Person | Seat |
|---|---|
| Dwight Gary Gilliland Other companies: Labcorp Holdings Inc. (Director · Since at least Oct 30, 2017) | Director · Jul 28, 2021 – Jun 12, 2024 · Past |
| Benjamin Lane | See Remarks · Since at least Mar 16, 2026 |
| Christopher Durant Turner | Chief Medical Officer · Since at least Jul 28, 2021 |
| Constantin Fest | Investor Relations · Since at least Jun 9, 2026 |
| Darlene Noci | Chief Development Officer · Since at least Jul 28, 2021 |
| Deborah Ann Miller | Chief Legal Officer · Since at least Jul 28, 2021 |
| Emily Conley | Director · Feb 2, 2022 – Aug 23, 2024 · Past |
| Georg Pirmin Meyer | Chief International Officer · Since at least May 27, 2026 |
| Henry E Pelish | Chief Scientific Officer · Since at least Jul 9, 2024 |
| James Richard Porter | President and CEO, Director · Since at least Jul 28, 2021 |
| Joseph Pearlberg | Director · Since at least Jul 28, 2021 |
| Matthew Shair | Director · Since at least Jul 28, 2021 |
| Michael L Meyers | Director · Since at least Oct 4, 2022 |
| Robert Bowers Jackson | Director · Jul 28, 2021 – Jul 28, 2021 · Past |
Log in to ask 6ix AI your own questions about Nuvalent, Inc.